Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update


Johnson, JA, Caudle, KE, Gong, L, Whirl-Carrillo, M, Stein, CM, Scott, SA, Lee, MT, Gage, BF, Kimmel, SE, Perera, MA et al (show 6 more authors) (2017) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. CLINICAL PHARMACOLOGY & THERAPEUTICS, 102 (3). pp. 397-404.

[img] Text
warfarin guideline 2017 update supplement revised_01102017.pdf - Author Accepted Manuscript
Download (673kB)
[img] Text
CPIC warfarin guideline 2017 update revised final.pdf - Author Accepted Manuscript
Download (930kB)

Abstract

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

Item Type: Article
Uncontrolled Keywords: Humans, Warfarin, Anticoagulants, Pharmacogenetics, Dose-Response Relationship, Drug, Genotype, Adult, Child, Practice Guidelines as Topic, Vitamin K Epoxide Reductases, Cytochrome P-450 CYP2C9, Cytochrome P450 Family 4
Depositing User: Symplectic Admin
Date Deposited: 28 Feb 2017 09:18
Last Modified: 19 Jan 2023 07:15
DOI: 10.1002/cpt.668
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3006093
Dimensions
Altmetric
CORE (COnnecting REpositories)